Dr. Mark Anderson, PhD, is a Principal Scientist in the Infectious Disease Research program at Abbott Laboratories where he manages the Hepatitis Biomarkers and Global Virus Surveillance teams. The Hepatitis Biomarkers team conducts research and development for serological and molecular biomarker assays to investigate ongoing questions in viral hepatitis. The Global Virus Surveillance team collects and performs testing on diverse strains of HBV, HCV, HIV, and SARS-CoV-2 from around the world to ensure Abbott diagnostic assays robustly detect rare and/or unique viral variants.
At Abbott, Dr. Anderson has worked on the development of hepatitis B research assays for the detection of HBsAg/anti-HBs immune complexes, HBsAg Isoforms, and HBV pgRNA. Dr. Anderson has engaged in collaborative research studies with both academic institutions and pharmaceutical companies to study the utility of novel HBV biomarkers in staging disease, viral responses to experimental HBV therapeutics, and off therapy outcomes.
Dr. Anderson has authored over 35 scientific publications. Before joining Abbott in 2018, he received his doctoral training at The University of Chicago and completed post-doctoral research studies at the Pasteur Institute in France.
